2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Breast Neoplasms
6392
Neoplasms
5365
Prostatic Neoplasms
2966
Carcinoma, Non-Small-Cell Lung
2709
Colorectal Neoplasms
2679
Lung Neoplasms
2267
Multiple Myeloma
1663
Lymphoma
1600
Neoplasm Metastasis
1552
Leukemia, Myeloid, Acute
1540
Melanoma
1486
Pancreatic Neoplasms
1470
Ovarian Neoplasms
1423
Leukemia
1389
Head and Neck Neoplasms
1284
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1282
Lymphoma, Non-Hodgkin
1231
Colonic Neoplasms
1159
Carcinoma, Hepatocellular
1142
Stomach Neoplasms
1129
Leukemia, Lymphocytic, Chronic, B-Cell
1090
Brain Neoplasms
1050
Rectal Neoplasms
980
Lymphoma, Follicular
979
Recurrence
976
Uterine Cervical Neoplasms
926
Glioblastoma
920
Carcinoma, Renal Cell
882
Lymphoma, Large B-Cell, Diffuse
853
Hodgkin Disease
777
Interventions
trametinib
1
dabrafenib
1
Thyrotropin Alfa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
×
Clear all
NCT03244956
2026-03-23
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Completed
40 enrolled